Propanc Biopharma Commences Drug Discovery Research Collaboration

Propanc Biopharma, Inc., a clinical stage biopharmaceutical company focused on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced that a cooperation agreement has been entered into between the University of Jaén and Propanc to commence the POP1 joint drug discovery program to be co-funded by both parties. The agreement coincides with the appointment of research scientist, Mr. Aitor González, to lead the drug discovery and research activities over the next 3 to 4 years. The objective of the program is to identify and develop suitable backup compounds to Propanc’s lead product candidate, PRP.

As part of the agreement, Macarena Perán, Ph.D. and Julian Kenyon, M.D. have been appointed as joint supervisors, representing the University and Propanc, respectively. The program involves advancing new compounds through a drug screening process, followed by preclinical and early stage clinical development. As the drug candidate progresses along the development pathway, the collaboration will also involve the Universities of Granada and Jaén, as well as Granada and Almeria Hospitals, which are members of FIBAO, a Public Health Foundation, based in Granada, Spain, committed to assisting commercial partners with the development and commercialization of innovative technologies designed to benefit humankind.

"Identifying and developing back up compounds to our lead product candidate, PRP, is part of our long-term vision to commercialize targeted therapies which treat and prevent the spread of cancer, but without the side effects normally associated with standard treatment approaches," said Dr. Julian Kenyon, Propanc’s Chief Scientific Officer. "The world-class facilities and expert scientific researchers at Jaén and Granada Universities are dedicated to helping us achieve our vision, and we look forward to deepening our pipeline through this research collaboration."

"Dr. Kenyon’s efforts in driving the understanding of the anti-tumor effects of proenzymes continues to be a world first, and we are truly excited to be leading this research collaboration on behalf of Propanc," said Dr. Macarena Perán, lecturer and reader at the University of Jaén, as well as joint supervisor of the POP1 drug discovery program. "Mr. González has been working in our laboratory over the past year and has experience in cell culture, nanoparticles, cancer stem cells and in vivo testing methodologies. We are highly confident in his ability to lead this research in the laboratory on behalf of our organizations."

Register as Visitor to CPhI China 2019!

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.